Technical Analysis for CYDY - Cytodyn Inc

Grade Last Price % Change Price Change
F 1.5 7.14% 0.1000
CYDY closed up 7.14 percent on Wednesday, October 20, 2021, on 82 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical CYDY trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 7.14%
NR7 Range Contraction 7.14%
Inside Day Range Contraction 7.14%
Wide Bands Range Expansion 7.14%
Oversold Stochastic Weakness 7.14%
Narrow Range Bar Range Contraction 7.91%
Wide Bands Range Expansion 7.91%
Oversold Stochastic Weakness 7.91%
Older End-of-Day Signals for CYDY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 14 hours ago
Rose Above Previous Day's High about 14 hours ago
Up 3% about 14 hours ago
Up 2% about 14 hours ago
Up 1% about 14 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cytodyn Inc Description

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Medical Specialties Antibodies Antigen Monoclonal Antibody Monoclonal Antibodies Belo Viruses Deficiency Hiv Stage Biotechnology T Cell Immunodeficiency Hiv/Aids Lymphocyte Chemokine Lentiviruses Animal Virology Antiviral Drug Virus (Hiv) Infection

Is CYDY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.34
52 Week Low 1.25
Average Volume 2,044,706
200-Day Moving Average 2.6940
50-Day Moving Average 1.6152
20-Day Moving Average 1.7935
10-Day Moving Average 1.5395
Average True Range 0.1432
ADX 25.55
+DI 20.6158
-DI 28.5707
Chandelier Exit (Long, 3 ATRs) 2.1104
Chandelier Exit (Short, 3 ATRs) 1.7796
Upper Bollinger Bands 2.4175
Lower Bollinger Band 1.1695
Percent B (%b) 0.26
BandWidth 69.5846
MACD Line -0.0888
MACD Signal Line -0.0300
MACD Histogram -0.0588
Fundamentals Value
Market Cap 856.13 Million
Num Shares 571 Million
EPS -0.19
Price-to-Earnings (P/E) Ratio -7.98
Price-to-Sales 0.00
Price-to-Book 548.48
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.7100
Resistance 3 (R3) 1.6933 1.6067 1.6750
Resistance 2 (R2) 1.6067 1.5532 1.6150 1.6633
Resistance 1 (R1) 1.5533 1.5201 1.5800 1.5700 1.6517
Pivot Point 1.4667 1.4667 1.4800 1.4750 1.4667
Support 1 (S1) 1.4133 1.4132 1.4400 1.4300 1.3483
Support 2 (S2) 1.3267 1.3801 1.3350 1.3367
Support 3 (S3) 1.2733 1.3267 1.3250
Support 4 (S4) 1.2900